Absci

Absci is a clinical-stage biopharmaceutical company that applies generative AI, synthetic biology, and cell‑line engineering to accelerate discovery and development of biologic therapeutics. Its proprietary platform combines machine learning–driven protein design with high‑throughput lab workflows and engineered cell lines to generate and optimize expressible, developable candidates more quickly. Absci advances its own clinical programs and collaborates with biopharma partners to discover and progress novel protein and antibody-based medicines. Companies work with Absci for an AI‑driven, end‑to‑end discovery engine that shortens timelines and de‑risks biologics development.